Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.52 |
| ▸ | NOS2 | P35228 | 2/20 | 0.52 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.45 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | HTR5A | P47898 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | PRKACA | P17612 | 2/20 | 0.41 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10205841 | 0.82 | PTGS1 (0.46) | NOS3NOS2CDK5CDK5R1KDM4E | |
| SCHEMBL10696459 | 0.81 | NOS3 (0.48) | NOS3NOS2KDM4EALDH1A1HPGD | |
| SCHEMBL27843373 | 0.80 | CDK5 (0.45) | CDK5CDK5R1KDM4EALDH1A1HPGD | |
| SCHEMBL4058635 | 0.79 | CDK5 (0.47) | CDK5CDK5R1KDM4EALDH1A1HPGD | |
| SCHEMBL2482626 | 0.79 | KDM4E (0.50) | NOS3NOS2CDK5CDK5R1KDM4E | |
| Ammonia Solution, Strong SCHEMBL28695759 | 0.78 | KDM4E (0.48) | NOS3NOS2CDK5CDK5R1KDM4E | |
| SCHEMBL29987004 | 0.78 | KDM4E (0.48) | NOS3NOS2CDK5CDK5R1KDM4E | |
| SCHEMBL28145706 | 0.76 | CDK5 (0.45) | CDK5CDK5R1KDM4EALDH1A1HPGD | |
| SCHEMBL1251654 | 0.76 | KDM4E (0.53) | CDK5CDK5R1KDM4EALDH1A1HPGD | |
| SCHEMBL18957021 | 0.76 | CDK5 (0.45) | CDK5CDK5R1KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025896-A1 | PROCESS FOR PREPARING 7-CHLORO-6-FLUORO-1-(2-ISOPROPYL-4-METHYLPYRIDIN-3-YL)PYRIDO[2,3-D]PYRIMIDINE-2,4(1H,3H)-DIONE | AMGEN INC. (US) | 2024-01-25 | — | — | US | disclosed |
| US-20230192682-A1 | IMPROVED SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192681-A1 | IMPROVED SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230121955-A1 | COMBINATION THERAPY INCLUDING A KRAS G12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS | AMGEN INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-20220220112-A1 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. | 2022-07-14 | — | — | US | disclosed |
| US-20200222407-A1 | COMBINATION THERAPY INCLUDING A KRAS G12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS | AMGEN INC. | 2020-07-16 | — | — | US | disclosed |
| CN-1137523-A | Indazoles and use thereof | MITSUBISHI CHEM CORP (JP) | 1996-12-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025896-A1 | PROCESS FOR PREPARING 7-CHLORO-6-FLUORO-1-(2-ISOPROPYL-4-METHYLPYRIDIN-3-YL)PYRIDO[2,3-D]PYRIMIDINE-2,4(1H,3H)-DIONE | HINT1, DPYD, NME2 | NOS3 4201/4885NOS2 3022/4885CDK5 907/4885 |
| US-20230121955-A1 | COMBINATION THERAPY INCLUDING A KRAS G12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS | KRAS, NRAS, HRAS | NOS3 4731/4885NOS2 4746/4885CDK5 1266/4885 |
| US-20230192681-A1 | IMPROVED SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | KRAS, NRAS, HRAS | NOS3 4807/4885NOS2 4821/4885CDK5 883/4885 |
| US-20230192682-A1 | IMPROVED SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | KRAS, NRAS, HRAS | NOS3 4292/4885NOS2 4284/4885CDK5 617/4885 |
| US-20200222407-A1 | COMBINATION THERAPY INCLUDING A KRAS G12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS | KRAS, NRAS, HRAS | NOS3 4731/4885NOS2 4746/4885CDK5 1266/4885 |
| US-20220220112-A1 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | KRAS, NRAS, HRAS | NOS3 4651/4885NOS2 4647/4885CDK5 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.